

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 8 AUGUST 2019**

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**Circular**”) of PuraPharm Corporation Limited (the “**Company**”) dated 24 July 2019 in relation to the connected transaction and proposed issue of new Shares under Specific Mandate for Capitalisation of the Shareholder’s Loan. The capitalised terms used in this announcement shall have the same meaning as those defined in the Circular unless otherwise defined herein.

The board of directors (the “**Board**”) of the Company is pleased to announce that at the extraordinary general meeting held on Thursday, 8 August 2019 (the “**EGM**”), all the proposed resolutions as set out in the EGM Notice were duly passed by the shareholders of the Company by way of poll. The poll results in respect of all the resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1.	To approve, confirm and ratify the Loan Capitalisation Agreement (as defined in the circular of the company dated 24 July 2019) (a copy of which has been produced to the meeting and initialled by the chairman of the meeting for identification purpose) and the transactions contemplated thereunder and the implementation thereof.	27,359,145 (99.93%)	19,500 (0.07%)
2.	To grant the Specific Mandate (as defined in the circular of the company dated 24 July 2019) for the allotment and issue of the 15,544,041 capitalisation shares at the issue price of HK\$1.93 per capitalisation shares to Mr. Chan Yu Ling, Abraham.	27,359,645 (99.93%)	19,000 (0.07%)

Ordinary Resolutions		Number of votes (%)	
		For	Against
3.	To authorise any one director of the Company (or any two directors of the Company or one director and the secretary of the Company, in the case of execution of documents under seal) for and on behalf of the Company to execute all such other documents, instruments and agreements and to do all such acts or things deemed by him/her to be incidental to, ancillary to or in connection with the matters contemplated in the Loan Capitalisation Agreement and the transactions contemplated thereunder and the implementation thereof including the affixing of seal thereon.	27,359,145 (99.93%)	19,500 (0.07%)

For details of the aforesaid resolutions, shareholders of the Company may refer to the EGM Notice and the Circular.

As more than 50% of the votes were cast in favour of each of the resolutions, all of the above resolutions were duly passed as ordinary resolutions of the Company.

As at the date of the EGM, the total number of issued shares of the Company was 247,717,920 Shares. As mentioned in the Circular, Mr. Chan Yu Ling, Abraham and his associates, together being interested in 130,065,720 Shares, representing approximately 52.51% of the total number of issued shares of the Company, were required to, and did, abstain from voting on the all resolutions at the EGM. The total number of Shares held by Independent Shareholders entitled to attend and vote for or against the ordinary resolution was 117,652,200 Shares. No shareholder was entitled to attend and vote only for or against any of the resolutions at the EGM.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 8 August 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie and Ms. Man Yee Wai, Viola; the non-executive director of the Company is Mr. Chow, Stanley and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.